Geode Capital Management LLC Has $48.19 Million Stake in TransMedics Group, Inc. (NASDAQ:TMDX)

Geode Capital Management LLC boosted its holdings in TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 1.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 772,744 shares of the company's stock after purchasing an additional 8,954 shares during the quarter. Geode Capital Management LLC owned approximately 2.30% of TransMedics Group worth $48,191,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Clear Creek Financial Management LLC bought a new stake in shares of TransMedics Group in the 4th quarter worth approximately $352,000. Vaughan Nelson Investment Management L.P. increased its stake in shares of TransMedics Group by 9.9% during the fourth quarter. Vaughan Nelson Investment Management L.P. now owns 361,615 shares of the company's stock valued at $22,547,000 after acquiring an additional 32,605 shares during the period. Baillie Gifford & Co. boosted its stake in TransMedics Group by 14.9% during the 4th quarter. Baillie Gifford & Co. now owns 269,836 shares of the company's stock valued at $16,824,000 after purchasing an additional 34,947 shares in the last quarter. State of Michigan Retirement System bought a new stake in shares of TransMedics Group in the 4th quarter worth $6,734,000. Finally, Peregrine Capital Management LLC boosted its stake in TransMedics Group by 64.0% during the fourth quarter. Peregrine Capital Management LLC now owns 66,140 shares of the company's stock valued at $4,124,000 after buying an additional 25,814 shares in the last quarter. 99.67% of the stock is owned by institutional investors and hedge funds.

TransMedics Group Stock Performance

TMDX stock traded up $2.86 on Friday, reaching $88.24. 971,082 shares of the company were exchanged, compared to its average volume of 1,338,951. The company has a debt-to-equity ratio of 2.42, a current ratio of 8.20 and a quick ratio of 7.33. The firm has a market capitalization of $2.97 billion, a PE ratio of 93.87 and a beta of 2.14. The stock's fifty day moving average price is $72.08 and its 200 day moving average price is $80.28. TransMedics Group, Inc. has a 12 month low of $55.00 and a 12 month high of $177.37.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on TMDX. Canaccord Genuity Group reaffirmed a "buy" rating and issued a $104.00 price objective on shares of TransMedics Group in a research note on Tuesday, March 11th. Needham & Company LLC reaffirmed a "hold" rating on shares of TransMedics Group in a report on Wednesday, March 26th. Three research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, TransMedics Group currently has a consensus rating of "Moderate Buy" and an average price target of $122.70.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.